Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q2 2018 · 10-Q
Revenue$245.50K$245.50K−26.8% vs Q2 2017 Net Income$111.23K$111.23KN/M vs Q2 2017 EPS Diluted-$0.50-$0.50N/M vs Q2 2017 Operating Income-$9,103,681N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,255,436N/M Margins · derivedOperating margin-3708.2%−1062.5 pt vs Q2 2017
Net margin45.3%+2669.5 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 1, 2018 · 32 d after period end